ArticleMedical care research and review : MCRR2014
Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs.
Article in Medical care research and review : MCRR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Quality of life as an outcome of opioid use disorder treatment: A systematic review.Journal of substance abuse treatment · 2017Pooled it
- Introduction of Medicare coverage in opioid treatment programs: Findings from the first three years.Journal of substance use and addiction treatment · 2024Article
- Internal and Environmental Predictors of Physician Practice Use of Screening and Medications for Opioid Use Disorders.Medical care research and review : MCRR · 2023Article
- Misalignment of Stakeholder Incentives in the Opioid Crisis.International journal of environmental research and public health · 2020Review
- A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice System.The International journal on drug policy · 2020Article
- The Association of State Opioid Misuse Prevention Policies With Patient- and Provider-Related Outcomes: A Scoping Review.The Milbank quarterly · 2020Article
- Correlates of Patient-Centered Care Practices at U.S. Substance Use Disorder Clinics.Psychiatric services (Washington, D.C.) · 2020Article
- Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Strengthening partnerships between substance use researchers and policy makers to take advantage of a window of opportunity.Substance abuse treatment, prevention, and policy · 2019Article
- State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder.Psychiatric services (Washington, D.C.) · 2018Article
- At the Expense of a Life: Race, Class, and the Meaning of Buprenorphine in Pharmaceuticalized "Care".Substance use & misuse · 2018Article
- A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees.Substance abuse · 2018Article
- Correlates of Motivational Interviewing Use Among Substance Use Treatment Programs Serving American Indians/Alaska Natives.The journal of behavioral health services & research · 2018Article
- A mixed methods study of HIV-related services in buprenorphine treatment.Substance abuse treatment, prevention, and policy · 2017Article
- Estimating State Transitions for Opioid Use Disorders.Medical decision making : an international journal of the Society for Medical Decision Making · 2017Article
- The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California.Addiction (Abingdon, England) · 2017Article
- Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.Psychiatric services (Washington, D.C.) · 2017Article
- Spillover effects of HIV testing policies: changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States.BMC public health · 2016Article
- Use of evidence-based treatments in substance abuse treatment programs serving American Indian and Alaska Native communities.Drug and alcohol dependence · 2016Article
- Lessons From Medicaid's Divergent Paths On Mental Health And Addiction Services.Health affairs (Project Hope) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This article examines changes from 2005 to 2011 in the use of an evidence-based clinical innovation, buprenorphine use, among a nationally representative sample of opioid treatment programs and identifies characteristics associated with its adoption. We apply a model of the adoption of clinical innovations that focuses on the work needs and characteristics of staff; organizations' technical and social support for the innovation; local market dynamics and competition; and state policies governing the innovation. Results indicate that buprenorphine use increased 24% for detoxification and 47% for maintenance therapy between 2005 and 2011. Buprenorphine use was positively related to reliance on private insurance and availability of state subsidies to cover its cost and inversely related to the percentage of clients who injected opiates, county size, and local availability of methadone. The results indicate that financial incentives and market factors play important roles in opioid treatment programs' decisions to adopt evidence-based clinical innovations such as buprenorphine use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.